New Research Explores on Cancer/Testis Antigen 1 - Pipeline Review, H1 2016

Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted pipeline therapeutics.

The report provides comprehensive information on the Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics development and features dormant and discontinued projects.

To view the table of contents and know more details please visit Cancer/Testis Antigen 1 - Pipeline Review, H1 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A)
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Cancer/Testis Antigen 1 (Autoimmunogenic Cancer/Testis Antigen NY-ESO-1 or Cancer/Testis Antigen 6.1 or L Antigen Family Member 2 or CTAG1A)
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

Aduro BioTech, Inc. Boehringer Ingelheim GmbH Celldex Therapeutics, Inc. GlaxoSmithKline Plc Immune Design Corp. ImmunoFrontier, Inc. Kite Pharma, Inc. Sanofi Pasteur SA Scancell Holdings Plc Vault Pharma Inc.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###